Technology area
Manufacturing & quality
658 funded awards, $527.3M total, FY2023-FY2025.
Where the money sat, by Institute / Center
IC funding decisions are set by portfolio priorities, NOFO scope, and program-officer judgment. These are funded records, not predictions of future funding.
| IC | Name | Records | Median award |
|---|---|---|---|
| AI (NIAID) | National Institute of Allergy and Infectious Diseases | 164 | $991,197 |
| CA (NCI) | National Cancer Institute | 96 | $887,944 |
| HL (NHLBI) | National Heart Lung and Blood Institute | 92 | $962,667 |
| DK (NIDDK) | National Institute of Diabetes and Digestive and Kidney Diseases | 51 | $959,868 |
| GM (NIGMS) | National Institute of General Medical Sciences | 46 | $701,383 |
| AG (NIA) | National Institute on Aging | 37 | $979,592 |
| NS (NINDS) | National Institute of Neurological Disorders and Stroke | 31 | $840,440 |
| HD (NICHD) | Eunice Kennedy Shriver National Institute of Child Health and Human Development | 28 | $850,099 |
| EY (NEI) | National Eye Institute | 26 | $766,450 |
| DA (NIDA) | National Institute on Drug Abuse | 13 | $377,843 |
| TR (NCATS) | National Center for Advancing Translational Sciences | 11 | $349,909 |
| OD | NIH Office of the Director | 11 | $994,272 |
| MH (NIMH) | National Institute of Mental Health | 9 | $947,109 |
| AR (NIAMS) | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 8 | $599,136 |
| AA (NIAAA) | National Institute on Alcohol Abuse and Alcoholism | 8 | $671,742 |
| DE (NIDCR) | National Institute of Dental and Craniofacial Research | 7 | $396,415 |
| AT (NCCIH) | National Center for Complementary and Integrative Health | 7 | $631,174 |
| ES (NIEHS) | National Institute of Environmental Health Sciences | 6 | $526,208 |
| HG (NHGRI) | National Human Genome Research Institute | 3 | $1,009,871 |
| EB (NIBIB) | National Institute of Biomedical Imaging and Bioengineering | 3 | $285,705 |
| NR (NINR) | National Institute of Nursing Research | 1 | $756,164 |
FOA / NOFO routes
Opportunity number prefixes: PA = Parent Announcement (broad, omnibus, multiple ICs), PAR = Parent with Special Review, PAS = Parent with set-aside funds, RFA = Request for Applications (targeted, single-IC, fixed budget). Status unknown means the pipeline has not verified whether the FOA is currently posting awards; the SBIR omnibus has been in reauthorization gap during this window. See the glossary for full definitions.
| Opportunity | Status | Records |
|---|---|---|
| PA-22-176 | unknown | 173 |
| PA-23-230 | unknown | 107 |
| PA-21-259 | unknown | 98 |
| PA-24-245 | unknown | 34 |
| PA-20-260 | unknown | 26 |
| PA-22-178 | unknown | 23 |
| PA-23-232 | unknown | 21 |
| PA-21-262 | unknown | 16 |
| PA-24-247 | unknown | 15 |
| PA-23-231 | unknown | 12 |
| PAS-22-196 | unknown | 11 |
| PA-22-177 | unknown | 10 |
| PA-20-265 | unknown | 9 |
| PAS-19-316 | unknown | 9 |
| PAS-22-197 | unknown | 8 |
| PA-19-272 | unknown | 8 |
| RFA-DA-23-021 | unknown | 7 |
| PA-20-262 | unknown | 6 |
| PA-21-345 | unknown | 6 |
| PA-21-260 | unknown | 5 |
| RFA-CA-22-025 | unknown | 5 |
| RFA-CA-21-001 | unknown | 5 |
| PA-24-246 | unknown | 5 |
| RFA-HL-23-009 | unknown | 4 |
| PA-20-272 | unknown | 4 |
| PA-18-574 | unknown | 3 |
| RFA-CA-23-034 | unknown | 2 |
| PA-25-212 | unknown | 2 |
| RFA-CA-22-017 | unknown | 2 |
| RFA-NS-20-009 | unknown | 2 |
| PAR-22-073 | unknown | 2 |
| PA-19-273 | unknown | 2 |
| RFA-HL-23-008 | unknown | 1 |
| RFA-NS-23-006 | unknown | 1 |
| PA-24-254 | unknown | 1 |
| PAR-20-129 | unknown | 1 |
| PA-23-233 | unknown | 1 |
| PAR-19-335 | unknown | 1 |
| RFA-DK-21-012 | unknown | 1 |
| RFA-HL-19-018 | unknown | 1 |
| PAR-20-098 | unknown | 1 |
| PAR-19-333 | unknown | 1 |
| RFA-NS-20-011 | unknown | 1 |
| PA-21-261 | unknown | 1 |
| RFA-DA-23-017 | unknown | 1 |
| PAR-23-032 | unknown | 1 |
| PA-21-071 | unknown | 1 |
| PA-21-268 | unknown | 1 |
Comparable funded projects
| ApplID | FY | IC | Title | Organization | Amount |
|---|---|---|---|---|---|
| 10598447 | 2025 | CA | Early clinical development of a novel IL-7R antibody for treating children with relapsed T-cell leukemia | FANNIN PARTNERS, LLC | $999,997 |
| 10845690 | 2025 | HL | Development of the Inspired Therapeutics NeoMate Mechanical Circulatory Support System for Neonates and Infants | INSPIRED THERAPEUTICS, LLC | $2,632,311 |
| 10850989 | 2025 | CA | CCR4-IL2 Bispecific Immunotoxin for Targeted Therapy of Cutaneous T-Cell Lymphoma | ROCK IMMUNE, INC. | $248,336 |
| 10932485 | 2025 | DE | RegendoGEL for guided pulp and dentin regeneration | REGENDODENT, INC. | $398,785 |
| 10997344 | 2025 | AI | A Vaccine for Lymphatic Filariasis, LFGuard™ | PAI LIFE SCIENCES, INC. | $452,996 |
| 10997370 | 2025 | AG | Development of a novel anti-neuroinflammatory experimental therapeutic for epilepsy and Alzheimer's risk | IMMUNOCHEM THERAPEUTICS, LLC | $1,209,751 |
| 10997404 | 2025 | AI | Recombinant Outer Membrane Vesicles as a Novel Adjuvant for a Malaria Vaccine | VERSATOPE THERAPEUTICS, INC. | $999,993 |
| 11001285 | 2025 | AR | Systemic Transplantation of MyoPAXon: IND Enabling Studies for the Treatment of DMD | MYOGENICA INC. | $1,266,814 |
Limitations
- RePORTER includes funded projects only, not unfunded applications.
- Panel sidebar reflects panels that have appeared on funded records, not future assignment.
- FOA-route status reflects verification at the timestamp shown.
- Tag 'manufacturing_or_quality' is a Cada controlled-vocabulary tag; see methodology for definitions.
Pattern read
Manufacturing and quality is a distinct tag in the dataset: median award $911K (the highest of any tag), 464 R44 vs only 91 R43 (a 5:1 ratio), and an unusually large R42 share (54 STTR Phase II awards). This is what a Phase II-dominated tag looks like. The work funded under 'manufacturing' is typically scale-up, GMP, or fill-finish work that is not appropriate for Phase I dollar levels. NIAID leads (164 records), reflecting vaccine/biologic manufacturing in the dataset window, with NCI (96) and NHLBI (92) following. Concentration is low at 4.9%.
Fit indicators
Watchouts